Patricia Aspichueta

THU-330-YI Hepatocyte desmosterol modulation influences the development of colorectal liver metastasis

Ane Nieva-Zuluaga, Ane Ortiz-Palma, Beatriz Arteta, Maider Apodaka-Biguri et autres

FRI-339 Acetyl-CoA carboxylase 2 inhibition in hepatic stellate cells drives their activation and enhances liver fibrosis

Tamara Parracho, Valentina Dorta, Marcos Fondevila, Jose Iglesias-Moure et autres

THU-164 The body roundness index as a novel anthropometric marker in metabolic-associated steatotic liver disease: findings from the HEPAMET registry

Douglas Maya-Miles, Rocio Aller, Javier Crespo, Luis Ibañez-Samaniego et autres

SAT-095-YI Dysregulation of the E2F2-PCSK9 axis promotes MASLD progression and related cardiovascular disease

Maider Apodaka-Biguri, BEATRIZ FERREIRA DOS SANTOS, Xabier Buqué, Ane Nieva-Zuluaga et autres

MARCO promotes cholangiocarcinogenesis by inducing immunosuppression and its targeting reduces tumor growth

Aloña Agirre-Lizaso, Maider Huici-Izagirre, Colm J. O’Rourke, Ekaterina Zhuravleva et autres

Abstract Cholangiocarcinoma (CCA) comprises a heterogeneous group of biliary malignant tumors with poor prognosis and limited therapeutic options. Recent studies have highlighted the role of the immune system in the development and progression of intrahepatic CCA (iCCA). In this study, we investigated …

es, dk, it, at, de, us, nl (code pays fourni par la source)

Inhibition of p107 alleviates liver steatosis by reducing de novo fatty acid synthesis

Juan Cuñarro, Marta Varela Miguens, Tadeu de Oliveira-Diz Tadeu, Xabier Buqué et autres

Abstract Metabolic dysfunction–associated steatotic liver disease (MASLD) is characterized by excessive hepatic lipid accumulation driven by increased de novo lipogenesis (DNL) and impaired lipid oxidation. p107, a member of the retinoblastoma (Rb) family, extensively studied in the context of cell cycle regulation …

es, fr, ch (code pays fourni par la source)

Lipidomics uncovers metabolic manifestations related to liver steatosis and low-grade systemic inflammation in diet-treated hereditary fructose intolerance patients

Javier de las Heras, María Unceta Suarez, Maria Mercado-Gómez, Leire Uraga Gracianteparaluceta et autres

BACKGROUND AND AIMS: Hereditary Fructose Intolerance (HFI), a rare autosomal recessive metabolic disorder, has historically been considered benign when treated with a lifelong fructose-, sucrose and sorbitol-restricted diet. However, adverse metabolic manifestations have recently been reported in treated HFI patients. As serum …

es (code pays fourni par la source)

Alcohol consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): understanding the gut–liver crosstalk for clinical translation

Raquel Benedé-Ubieto, Olga Estévez-Vázquez, Rana Acar, Hector Leal-Lassalle et autres

Objective In the present study, we investigated the role of the gut–liver crosstalk in the pathogenesis of steatotic liver disease (SLD) induced by the compounding and deleterious effects of alcohol and metabolic risk factors, and explored the potential translational aspects of microbiome-based …

es, us, tr, kr, ar, de, Zambie, se, nl, cl (code pays fourni par la source)

Statins halt polycystic liver disease by reprogramming metabolism and normalizing mitochondrial bioenergetics in cystic cholangiocytes

Enara Markaide, Laura Izquierdo‐Sánchez, Irene Olaizola, Josu Urretabizkaia-Garmendia et autres

BACKGROUND AND AIM: Polycystic liver disease (PLD) is a hereditary disorder characterized by the progressive development and enlargement of intrahepatic biliary cysts, which can lead to significant morbidity. Liver transplantation remains the only curative treatment. Mutations in endoplasmic reticulum (ER)-related genes contribute …

es, pt, nl (code pays fourni par la source)

V-21 - CLASSIFICATION OF MASH PATIENTS ACCORDING TO THE LIPIDOME HALLMARK ALLOWS THE IDENTIFICATION OF A SUBGROUP IN WHICH DNA DAMAGE IS A DETERMINING MECHANISM

Idoia Fernández-Puertas, Ibon Martínez-Arranz, Unai Garzon-Basterra, Xabier Buqué et autres

THE REMODELING OF CHOLESTEROL METABOLISM IN HEPATOCYTES MEDIATES COLORECTAL LIVER METASTASIS DEVELOPMENT

Ane Nieva-Zuluaga, Beatriz Arteta, Maider Apodaka-Biguri, Idoia Fernández-Puertas et autres

BODY ROUNDNESS INDEX Y ENFERMEDAD HEPÁTICA METABÓLICA: UNA NUEVA APROXIMACIÓN ANTROPOMÉTRICA. RESULTADOS DEL REGISTRO HEPAMET

Douglas Maya Miles, R. Aller, Javier Crespo, Luis Ibañez-Samaniego et autres